Biological agents in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis
- VernacularTitle:生物制剂治疗中重度斑块状银屑病及关节病型银屑病的进展
- Author:
Rong GAO
1
;
Lan ZHANG
;
Zhengxiao LI
Author Information
- Keywords: Psoriasis; Biological agents; Tumor necrosis factor-alpha; Interleukins; Treatment outcome; Moderate to severe plaque psoriasis; Psoriatic arthritis
- From: Chinese Journal of Dermatology 2022;55(1):72-75
- CountryChina
- Language:Chinese
- Abstract: Psoriasis is an immune-mediated chronic recurrent inflammatory disease, and biological agents targeting cytokines and their receptors involved in its pathogenesis have become an increasingly important option for its treatment in recent years. With the successive appearance of biological agents such as secukinumab and ustekinumab on the market in China, the use of biologics will become increasingly common in the treatment of psoriasis. This review summarizes the efficacy of different biological agents and individualized drug selection in the treatment of moderate to severe plaque psoriasis and psoriatic arthritis, with a view to providing a reference for physicians in clinical practice.
